Aegerion Resolves FDA Warning About Juxtapid Promotion But DOJ Probe Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Corrective broadcast clarifying statements its CEO made on CNBC’s “Fast Money” produces a close-out letter, but the firm emphasizes the cost and risks of a DOJ investigation.